EUVIMEDEUVIMED entdecken
Leserbrief

Interpreting romosozumab for cancer treatment-induced bone loss: measurement, missing data, and surveillance

Mehmet Serkan Kılıçoğlu

Osteoporosis International · 2026-10 · 37 (10) · 2763-2764

DOI: 10.1007/s00198-026-08234-9 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Osteoporosis International, online erschienen am 24.09.2026. Verfasst von Mehmet Serkan Kılıçoğlu. Beteiligte Einrichtung: Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Bezmialem Vakif University, 34093, Fatih, Istanbul, Türkiye. dr.serkan.kilic…. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Bezmialem Vakif University, 34093, Fatih, Istanbul, Türkiye. dr.serkan.kilicoglu@gmail.com.

Zitieren

APA

Kılıçoğlu, M. S. (2026). Interpreting romosozumab for cancer treatment-induced bone loss: measurement, missing data, and surveillance. Osteoporosis International, 37(10), 2763-2764. https://doi.org/10.1007/s00198-026-08234-9

Vancouver

Kılıçoğlu MS. Interpreting romosozumab for cancer treatment-induced bone loss: measurement, missing data, and surveillance. Osteoporosis International. 2026;37(10):2763-2764. doi:10.1007/s00198-026-08234-9

BibTeX
@article{Klolu2026,
  author = {Kılıçoğlu, Mehmet Serkan},
  title = {Interpreting romosozumab for cancer treatment-induced bone loss: measurement, missing data, and surveillance},
  journal = {Osteoporosis International},
  year = {2026},
  volume = {37},
  number = {10},
  pages = {2763--2764},
  doi = {10.1007/s00198-026-08234-9}
}
Kostenlos starten →